6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
ONGLYZA O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
are O
upper O
respiratory O
tract O
infection O
, O
urinary O
tract O
infection O
, O
and O
headache O
. O

( O
6.1 O
) O
* O
Peripheral O
edema O
was O
reported O
more O
commonly O
in O
patients O
treated O
with O
the O
combination O
of O
ONGLYZA O
and O
a O
thiazolidinedione O
( O
TZD O
) O
than O
in O
patients O
treated O
with O
the O
combination O
of O
placebo O
and O
TZD O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
with O
Monotherapy O
and O
with O
Add-On O
Combination O
Therapy O
In O
two O
placebo-controlled O
monotherapy O
trials O
of O
24-weeks O
duration O
, O
patients O
were O
treated O
with O
ONGLYZA O
2.5 O
mg O
daily O
, O
ONGLYZA O
5 O
mg O
daily O
, O
and O
placebo O
. O

Three O
24-week O
, O
placebo-controlled O
, O
add-on O
combination O
therapy O
trials O
were O
also O
conducted O
: O
one O
with O
metformin O
, O
one O
with O
a O
thiazolidinedione O
( O
pioglitazone O
or O
rosiglitazone O
) O
, O
and O
one O
with O
glyburide O
. O

In O
these O
three O
trials O
, O
patients O
were O
randomized O
to O
add-on O
therapy O
with O
ONGLYZA O
2.5 O
mg O
daily O
, O
ONGLYZA O
5 O
mg O
daily O
, O
or O
placebo O
. O

A O
saxagliptin O
10 O
mg O
treatment O
arm O
was O
included O
in O
one O
of O
the O
monotherapy O
trials O
and O
in O
the O
add-on O
combination O
trial O
with O
metformin O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

In O
a O
prespecified O
pooled O
analysis O
of O
the O
24-week O
data O
( O
regardless O
of O
glycemic O
rescue O
) O
from O
the O
two O
monotherapy O
trials O
, O
the O
add-on O
to O
metformin O
trial O
, O
the O
add-on O
to O
thiazolidinedione O
( O
TZD O
) O
trial O
, O
and O
the O
add-on O
to O
glyburide O
trial O
, O
the O
overall O
incidence O
of O
adverse O
events O
in O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
was O
similar O
to O
placebo O
( O
72 O
% O
and O
72.2 O
% O
versus O
70.6 O
% O
, O
respectively O
) O
. O

Discontinuation O
of O
therapy O
due O
to O
adverse O
events O
occurred O
in O
2.2 O
% O
, O
3.3 O
% O
, O
and O
1.8 O
% O
of O
patients O
receiving O
ONGLYZA O
2.5 O
mg O
, O
ONGLYZA O
5 O
mg O
, O
and O
placebo O
, O
respectively O
. O

The O
most O
common O
adverse O
events O
( O
reported O
in O
at O
least O
2 O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
or O
at O
least O
2 O
patients O
treated O
with O
ONGLYZA O
5 O
mg O
) O
associated O
with O
premature O
discontinuation O
of O
therapy O
included O
lymphopenia B-OSE_Labeled_AE
( O
0.1 O
% O
and O
0.5 O
% O
versus O
0 O
% O
, O
respectively O
) O
, O
rash B-OSE_Labeled_AE
( O
0.2 O
% O
and O
0.3 O
% O
versus O
0.3 O
% O
) O
, O
blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.3 O
% O
and O
0 O
% O
versus O
0 O
% O
) O
, O
and O
blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.1 O
% O
and O
0.2 O
% O
versus O
0 O
% O
) O
. O

The O
adverse O
reactions O
in O
this O
pooled O
analysis O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
ONGLYZA O
5 O
mg O
, O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
are O
shown O
in O
Table O
1 O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
Placebo-Controlled O
TrialsThe O
5 O
placebo-controlled O
trials O
include O
two O
monotherapy O
trials O
and O
one O
add-on O
combination O
therapy O
trial O
with O
each O
of O
the O
following O
: O
metformin O
, O
thiazolidinedione O
, O
or O
glyburide O
. O

Table O
shows O
24-week O
data O
regardless O
of O
glycemic O
rescue O
. O

Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
with O
ONGLYZA O
5 O
mg O
and O
More O
Commonly O
than O
in O
Patients O
Treated O
with O
Placebo O
Number O
( O
% O
) O
of O
Patients O
ONGLYZA O
5 O
mg O
N=882 O
Placebo O
N=799 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
68 O
( O
7.7 O
) O
61 O
( O
7.6 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
60 O
( O
6.8 O
) O
49 O
( O
6.1 O
) O
Headache B-OSE_Labeled_AE
57 O
( O
6.5 O
) O
47 O
( O
5.9 O
) O
In O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
, O
headache B-OSE_Labeled_AE
( O
6.5 O
% O
) O
was O
the O
only O
adverse O
reaction O
reported O
at O
a O
rate O
> O
=5 O
% O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
. O

In O
this O
pooled O
analysis O
, O
adverse O
reactions O
that O
were O
reported O
in O
> O
=2 O
% O
of O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
or O
ONGLYZA O
5 O
mg O
and O
> O
=1 O
% O
more O
frequently O
compared O
to O
placebo O
included O
: O
sinusitis B-OSE_Labeled_AE
( O
2.9 O
% O
and O
2.6 O
% O
versus O
1.6 O
% O
, O
respectively O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
2.4 O
% O
and O
1.7 O
% O
versus O
0.5 O
% O
) O
, O
gastroenteritis B-OSE_Labeled_AE
( O
1.9 O
% O
and O
2.3 O
% O
versus O
0.9 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
( O
2.2 O
% O
and O
2.3 O
% O
versus O
1.3 O
% O
) O
. O

In O
the O
add-on O
to O
TZD O
trial O
, O
the O
incidence O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
was O
higher O
for O
ONGLYZA O
5 O
mg O
versus O
placebo O
( O
8.1 O
% O
and O
4.3 O
% O
, O
respectively O
) O
. O

The O
incidence O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
was O
3.1 O
% O
. O

None O
of O
the O
reported O
adverse O
reactions O
of O
peripheral B-NonOSE_AE
edema I-NonOSE_AE
resulted O
in O
study O
drug O
discontinuation O
. O

Rates O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
versus O
placebo O
were O
3.6 O
% O
and O
2 O
% O
versus O
3 O
% O
given O
as O
monotherapy O
, O
2.1 O
% O
and O
2.1 O
% O
versus O
2.2 O
% O
given O
as O
add-on O
therapy O
to O
metformin O
, O
and O
2.4 O
% O
and O
1.2 O
% O
versus O
2.2 O
% O
given O
as O
add-on O
therapy O
to O
glyburide O
. O

The O
incidence O
rate O
of O
fractures B-OSE_Labeled_AE
was O
1.0 O
and O
0.6 O
per O
100 O
patient-years O
, O
respectively O
, O
for O
ONGLYZA O
( O
pooled O
analysis O
of O
2.5 O
mg O
, O
5 O
mg O
, O
and O
10 O
mg O
) O
and O
placebo O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

The O
incidence O
rate O
of O
fracture B-NonOSE_AE
events O
in O
patients O
who O
received O
ONGLYZA O
did O
not O
increase O
over O
time O
. O

Causality O
has O
not O
been O
established O
and O
nonclinical O
studies O
have O
not O
demonstrated O
adverse O
effects O
of O
ONGLYZA O
on O
bone O
. O

An O
event O
of O
thrombocytopenia B-NonOSE_AE
, O
consistent O
with O
a O
diagnosis O
of O
idiopathic B-NonOSE_AE
thrombocytopenic I-NonOSE_AE
purpura I-NonOSE_AE
, O
was O
observed O
in O
the O
clinical O
program O
. O

The O
relationship O
of O
this O
event O
to O
ONGLYZA O
is O
not O
known O
. O

Adverse O
Reactions O
in O
Patients O
with O
Renal O
Impairment O
ONGLYZA O
2.5 O
mg O
was O
compared O
to O
placebo O
in O
a O
12-week O
trial O
in O
170 O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
and O
moderate O
or O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
end B-Not_AE_Candidate
- I-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
ESRD O
) O
. O

The O
incidence O
of O
adverse O
events O
, O
including O
serious O
adverse O
events O
and O
discontinuations O
due O
to O
adverse O
events O
, O
was O
similar O
between O
ONGLYZA O
and O
placebo O
. O

Adverse O
Reactions O
with O
Concomitant O
Use O
with O
Insulin O
In O
the O
add-on O
to O
insulin O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
the O
incidence O
of O
adverse O
events O
, O
including O
serious O
adverse O
events O
and O
discontinuations O
due O
to O
adverse O
events O
, O
was O
similar O
between O
ONGLYZA O
and O
placebo O
, O
except O
for O
confirmed O
hypoglycemia B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Adverse O
Reactions O
with O
Concomitant O
Use O
with O
Metformin O
in O
Treatment-Naive O
Patients O
with O
Type O
2 O
Diabetes O
Table O
2 O
shows O
the O
adverse O
reactions O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
> O
=5 O
% O
of O
patients O
participating O
in O
an O
additional O
24-week O
, O
active-controlled O
trial O
of O
coadministered O
ONGLYZA O
and O
metformin O
in O
treatment-naive O
patients O
. O

Table O
2 O
: O
Initial O
Therapy O
with O
Combination O
of O
ONGLYZA O
and O
Metformin O
in O
Treatment-Naive O
Patients O
: O
Adverse O
Reactions O
Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
with O
Combination O
Therapy O
of O
ONGLYZA O
5 O
mg O
Plus O
Metformin O
( O
and O
More O
Commonly O
than O
in O
Patients O
Treated O
with O
Metformin O
Alone O
) O
Number O
( O
% O
) O
of O
Patients O
ONGLYZA O
5 O
mg O
+ O
Metformin O
N=320 O
Metformin O
N=328 O
Headache B-OSE_Labeled_AE
24 O
( O
7.5 O
) O
17 O
( O
5.2 O
) O
Nasopharyngitis B-OSE_Labeled_AE
22 O
( O
6.9 O
) O
13 O
( O
4.0 O
) O
Hypoglycemia O
Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
hypoglycemia B-NonOSE_AE
. O

A O
concurrent O
glucose O
measurement O
was O
not O
required O
or O
was O
normal O
in O
some O
patients O
. O

Therefore O
, O
it O
is O
not O
possible O
to O
conclusively O
determine O
that O
all O
these O
reports O
reflect O
true O
hypoglycemia B-NonOSE_AE
. O

In O
the O
add-on O
to O
glyburide O
study O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-OSE_Labeled_AE
was O
higher O
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
( O
13.3 O
% O
and O
14.6 O
% O
) O
versus O
placebo O
( O
10.1 O
% O
) O
. O

The O
incidence O
of O
confirmed O
hypoglycemia B-OSE_Labeled_AE
in O
this O
study O
, O
defined O
as O
symptoms O
of O
hypoglycemia B-NonOSE_AE
accompanied O
by O
a O
fingerstick O
glucose B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
was O
2.4 O
% O
and O
0.8 O
% O
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
and O
0.7 O
% O
for O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

The O
incidence O
of O
reported O
hypoglycemia B-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
versus O
placebo O
given O
as O
monotherapy O
was O
4 O
% O
and O
5.6 O
% O
versus O
4.1 O
% O
, O
respectively O
, O
7.8 O
% O
and O
5.8 O
% O
versus O
5 O
% O
given O
as O
add-on O
therapy O
to O
metformin O
, O
and O
4.1 O
% O
and O
2.7 O
% O
versus O
3.8 O
% O
given O
as O
add-on O
therapy O
to O
TZD O
. O

The O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
3.4 O
% O
in O
treatment-naive O
patients O
given O
ONGLYZA O
5 O
mg O
plus O
metformin O
and O
4 O
% O
in O
patients O
given O
metformin O
alone O
. O

In O
the O
active-controlled O
trial O
comparing O
add-on O
therapy O
with O
ONGLYZA O
5 O
mg O
to O
glipizide O
in O
patients O
inadequately O
controlled O
on O
metformin O
alone O
, O
the O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
3 O
% O
( O
19 O
events O
in O
13 O
patients O
) O
with O
ONGLYZA O
5 O
mg O
versus O
36.3 O
% O
( O
750 O
events O
in O
156 O
patients O
) O
with O
glipizide O
. O

Confirmed O
symptomatic O
hypoglycemia B-NonOSE_AE
( O
accompanying O
fingerstick O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
was O
reported O
in O
none O
of O
the O
ONGLYZA-treated O
patients O
and O
in O
35 O
glipizide-treated O
patients O
( O
8.1 O
% O
) O
( O
p O
< O
0.0001 O
) O
. O

During O
12 O
weeks O
of O
treatment O
in O
patients O
with O
moderate O
or O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
ESRD B-Not_AE_Candidate
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
20 O
% O
among O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
and O
22 O
% O
among O
patients O
treated O
with O
placebo O
. O

Four O
ONGLYZA-treated O
patients O
( O
4.7 O
% O
) O
and O
three O
placebo-treated O
patients O
( O
3.5 O
% O
) O
reported O
at O
least O
one O
episode O
of O
confirmed O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
( O
accompanying O
fingerstick O
glucose B-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
. O

In O
the O
add-on O
to O
insulin O
trial O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
18.4 O
% O
for O
ONGLYZA O
5 O
mg O
and O
19.9 O
% O
for O
placebo O
. O

However O
, O
the O
incidence O
of O
confirmed O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
( O
accompanying O
fingerstick O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
was O
higher O
with O
ONGLYZA O
5 O
mg O
( O
5.3 O
% O
) O
versus O
placebo O
( O
3.3 O
% O
) O
. O

In O
the O
add-on O
to O
metformin O
plus O
sulfonylurea O
trial O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
10.1 O
% O
for O
ONGLYZA O
5 O
mg O
and O
6.3 O
% O
for O
placebo O
. O

Confirmed O
hypoglycemia B-OSE_Labeled_AE
was O
reported O
in O
1.6 O
% O
of O
the O
ONGLYZA-treated O
patients O
and O
in O
none O
of O
the O
placebo-treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
such O
as O
urticaria B-OSE_Labeled_AE
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
in O
the O
5-study O
pooled O
analysis O
up O
to O
Week O
24 O
were O
reported O
in O
1.5 O
% O
, O
1.5 O
% O
, O
and O
0.4 O
% O
of O
patients O
who O
received O
ONGLYZA O
2.5 O
mg O
, O
ONGLYZA O
5 O
mg O
, O
and O
placebo O
, O
respectively O
. O

None O
of O
these O
events O
in O
patients O
who O
received O
ONGLYZA O
required O
hospitalization O
or O
were O
reported O
as O
life-threatening O
by O
the O
investigators O
. O

One O
ONGLYZA-treated O
patient O
in O
this O
pooled O
analysis O
discontinued O
due O
to O
generalized B-OSE_Labeled_AE
urticaria I-OSE_Labeled_AE
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Infections O
In O
the O
unblinded O
, O
controlled O
, O
clinical O
trial O
database O
for O
ONGLYZA O
to O
date O
, O
there O
have O
been O
6 O
( O
0.12 O
% O
) O
reports O
of O
tuberculosis B-OSE_Labeled_AE
among O
the O
4959 O
ONGLYZA-treated O
patients O
( O
1.1 O
per O
1000 O
patient-years O
) O
compared O
to O
no O
reports O
of O
tuberculosis B-NonOSE_AE
among O
the O
2868 O
comparator-treated O
patients O
. O

Two O
of O
these O
six O
cases O
were O
confirmed O
with O
laboratory O
testing O
. O

The O
remaining O
cases O
had O
limited O
information O
or O
had O
presumptive O
diagnoses O
of O
tuberculosis B-NonOSE_AE
. O

None O
of O
the O
six O
cases O
occurred O
in O
the O
United O
States O
or O
in O
Western O
Europe O
. O

One O
case O
occurred O
in O
Canada O
in O
a O
patient O
originally O
from O
Indonesia O
who O
had O
recently O
visited O
Indonesia O
. O

The O
duration O
of O
treatment O
with O
ONGLYZA O
until O
report O
of O
tuberculosis B-OSE_Labeled_AE
ranged O
from O
144 O
to O
929 O
days O
. O

Post-treatment O
lymphocyte O
counts O
were O
consistently O
within O
the O
reference O
range O
for O
four O
cases O
. O

One O
patient O
had O
lymphopenia B-Not_AE_Candidate
prior O
to O
initiation O
of O
ONGLYZA O
that O
remained O
stable O
throughout O
ONGLYZA O
treatment O
. O

The O
final O
patient O
had O
an O
isolated O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
below I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
approximately O
four O
months O
prior O
to O
the O
report O
of O
tuberculosis B-OSE_Labeled_AE
. O

There O
have O
been O
no O
spontaneous O
reports O
of O
tuberculosis B-NonOSE_AE
associated O
with O
ONGLYZA O
use O
. O

Causality O
has O
not O
been O
estimated O
and O
there O
are O
too O
few O
cases O
to O
date O
to O
determine O
whether O
tuberculosis B-NonOSE_AE
is O
related O
to O
ONGLYZA O
use O
. O

There O
has O
been O
one O
case O
of O
a O
potential O
opportunistic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
in O
the O
unblinded O
, O
controlled O
clinical O
trial O
database O
to O
date O
in O
an O
ONGLYZA-treated O
patient O
who O
developed O
suspected O
foodborne O
fatal B-NonOSE_AE
salmonella B-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
after O
approximately O
600 O
days O
of O
ONGLYZA O
therapy O
. O

There O
have O
been O
no O
spontaneous O
reports O
of O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
associated O
with O
ONGLYZA O
use O
. O

Vital O
Signs O
No O
clinically O
meaningful O
changes O
in O
vital O
signs O
have O
been O
observed O
in O
patients O
treated O
with O
ONGLYZA O
. O

Laboratory O
Tests O
Absolute O
Lymphocyte O
Counts O
There O
was O
a O
dose-related O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
count I-OSE_Labeled_AE
observed O
with O
ONGLYZA O
. O

From O
a O
baseline O
mean O
absolute O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
of O
approximately O
2200 O
cells/microL O
, O
mean I-OSE_Labeled_AE
decreases I-OSE_Labeled_AE
of O
approximately O
100 O
and O
120 O
cells/microL O
with O
ONGLYZA O
5 O
mg O
and O
10 O
mg O
, O
respectively O
, O
relative O
to O
placebo O
were O
observed O
at O
24 O
weeks O
in O
a O
pooled O
analysis O
of O
five O
placebo-controlled O
clinical O
studies O
. O

Similar O
effects O
were O
observed O
when O
ONGLYZA O
5 O
mg O
was O
given O
in O
initial O
combination O
with O
metformin O
compared O
to O
metformin O
alone O
. O

There O
was O
no O
difference O
observed O
for O
ONGLYZA O
2.5 O
mg O
relative O
to O
placebo O
. O

The O
proportion O
of O
patients O
who O
were O
reported O
to O
have O
a O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
microL I-OSE_Labeled_AE
was O
0.5 O
% O
, O
1.5 O
% O
, O
1.4 O
% O
, O
and O
0.4 O
% O
in O
the O
ONGLYZA O
2.5 O
mg O
, O
5 O
mg O
, O
10 O
mg O
, O
and O
placebo O
groups O
, O
respectively O
. O

In O
most O
patients O
, O
recurrence O
was O
not O
observed O
with O
repeated O
exposure O
to O
ONGLYZA O
although O
some O
patients O
had O
recurrent O
decreases O
upon O
rechallenge O
that O
led O
to O
discontinuation O
of O
ONGLYZA O
. O

The O
decreases B-NonOSE_AE
in I-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
were O
not O
associated O
with O
clinically O
relevant O
adverse O
reactions O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

The O
clinical O
significance O
of O
this O
decrease B-NonOSE_AE
in I-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
relative O
to O
placebo O
is O
not O
known O
. O

When O
clinically O
indicated O
, O
such O
as O
in O
settings O
of O
unusual O
or O
prolonged O
infection B-NonOSE_AE
, O
lymphocyte O
count O
should O
be O
measured O
. O

The O
effect O
of O
ONGLYZA O
on O
lymphocyte O
counts O
in O
patients O
with O
lymphocyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
( O
e.g. O
, O
human B-Not_AE_Candidate
immunodeficiency I-Not_AE_Candidate
virus I-Not_AE_Candidate
) O
is O
unknown O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
ONGLYZA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

